PTC-EM-AI Funding Program supports researchers advancing AI-discovered therapies through lead optimization and IND-enabling work to develop disease-modifying treatments for Alzheimer’s and related dementias.
The PTC-CTP grant from the Alzheimer's Association funds biomarker-driven clinical trials testing combination therapies for Alzheimer’s disease and related dementias.
Tau Pipeline Enabling Program V (T-PEP) supports researchers developing therapeutic candidates targeting tau or related mechanisms to advance potential disease-modifying treatments for tauopathies.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
Accelerating Drug Discovery for FTD supports investigators developing small molecule and biologic drugs through lead optimization and animal-model testing to advance disease-modifying treatments for FTD.
This grant supports academic and biotech researchers in developing new drugs to prevent, slow, or treat Alzheimer’s disease through preclinical and early-stage clinical research.